Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Eustace

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Oncotarget|October 25, 2016
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerSinead Toomey, Stephen F Madden, Simon J Furney, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
NPJ Breast Cancer|September 27, 2023
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancerNicola Cosgrove, Alex J Eustace, Peter O'Donovan, et al.
Breast Cancer Research : BCR|July 29, 2017
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapiesSinead Toomey, Alexander J Eustace, Joanna Fay, et al.
BMC Cancer|October 12, 2018
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAILAlex J Eustace, Neil T Conlon, Martina S J McDermott, et al.
JCI Insight|July 19, 2022
An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinasesChristian T Stackhouse, Joshua C Anderson, Zongliang Yue, et al.
Breast Cancer Research and Treatment|May 13, 2021
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancerA J Eustace, S F Madden, J Fay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M Collins, Stephen F Madden, Nicola Gaynor, et al.
Journal of Translational Medicine|February 24, 2020
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samplesSinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, et al.
Therapeutic Advances in Medical Oncology|August 7, 2019
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trialGiuseppe Gullo, Alex J Eustace, Alexandra Canonici, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Oncotarget|October 25, 2016
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancerSinead Toomey, Stephen F Madden, Simon J Furney, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
NPJ Breast Cancer|September 27, 2023
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancerNicola Cosgrove, Alex J Eustace, Peter O'Donovan, et al.
Breast Cancer Research : BCR|July 29, 2017
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapiesSinead Toomey, Alexander J Eustace, Joanna Fay, et al.
BMC Cancer|October 12, 2018
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAILAlex J Eustace, Neil T Conlon, Martina S J McDermott, et al.
JCI Insight|July 19, 2022
An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinasesChristian T Stackhouse, Joshua C Anderson, Zongliang Yue, et al.
Breast Cancer Research and Treatment|May 13, 2021
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancerA J Eustace, S F Madden, J Fay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M Collins, Stephen F Madden, Nicola Gaynor, et al.
Journal of Translational Medicine|February 24, 2020
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samplesSinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, et al.
Therapeutic Advances in Medical Oncology|August 7, 2019
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trialGiuseppe Gullo, Alex J Eustace, Alexandra Canonici, et al.
Pageof 13